Clinical-stage biotechnology company Rapport Therapeutics has raised USD 150 million in a Series B funding round led by Cormorant Asset Management, with participation from new investors including Fidelity Management & Research Company, Goldman Sachs Asset Management, and T. Rowe Price Associates, Inc., as well as all existing investors, including Third Rock Ventures, ARCH Venture Partners, and Johnson & Johnson Innovation - JJDC, Inc. (JJDC).
The funding will support the advancement of Rapport's pipeline of precision neurology drugs, including progressing current clinical programs for seizures and psychiatric conditions, as well as expanding into new indications using its receptor-targeting platform.
In conjunction with the financing, the company has elected two new boards of directors to advance the precision neuro medicine platform.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.